Form 4: Adaptive Biotechnologies Director Boosts Shareholding
Insider Transaction Report
Adaptive Biotechnologies Director Michelle Renee Griffin acquired 15,625 shares of common stock, increasing her beneficial ownership to 31,019 shares.
Summary
- Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corp (ADPT), acquired 15,625 shares of common stock.
- The transaction occurred on March 4, 2026, with a reported price of $0 per share, indicating a grant or award.
- Following this acquisition, Ms. Griffin's total beneficial ownership in Adaptive Biotechnologies Corp stands at 31,019 shares of common stock.
- The transaction was made pursuant to a Rule 10b5-1 trading plan.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development. An increase in director ownership, even through a grant, indicates continued alignment of interests and potential confidence in the company's trajectory.
Positives
- Increased insider ownership by a Director, Michelle Renee Griffin, which generally signals confidence in the company's future prospects.
- The acquisition aligns management's interests more closely with those of shareholders.
Industry Context
StockSavvy.ai notes that insider transactions, particularly acquisitions, are often monitored by investors as they can provide insights into management's perception of the company's value and future performance. While this acquisition was a grant (price $0), it still represents an increase in a director's stake, which is generally viewed as a positive signal of alignment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up pre-planned trades to avoid accusations of trading on material non-public information. | 03/04/2026 | Enhances transparency and provides a legal defense against insider trading allegations for the reporting person. |
Stakeholder Impact
- Shareholders: The increase in director ownership may be perceived positively, suggesting management's confidence and alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 03/04/2026 | Date of earliest transaction (acquisition of 15,625 shares of common stock). |
| 03/06/2026 | Date the Form 4 was signed by Michelle Renee Griffin's attorney-in-fact. |
Recommendation
buyA seasoned investor would view the increase in a director's beneficial ownership, even through a grant at a $0 price, as a positive signal. It demonstrates continued commitment and alignment of interests with shareholders, suggesting confidence in the company's long-term prospects. While not an open-market purchase, it still adds to the insider's stake.
Keywords
Adaptive Biotechnologies, ADPT, Insider Transaction, Form 4, Director Share Acquisition, Michelle Renee Griffin, Stock Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.